에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Biotech

Long Ideas

Health Care

Technicals

Politics

Trading Ideas

General

AMGN

일라이 릴리(NYSE:LLY)의 최근 주가가 하락세를 보이고 있다. 지난해 주가가 26.04% 상승했지만 최근 한 달 동안에는 17.24% 하락했다.

일라이 릴리의 주식은 케네디가 체중 감량 약물을 대상으로 하자 급락

News

Pre-Market Outlook

Markets

MRNA

MSFT

NVDA

TCOM

TSLA

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 더 하락했음을 나타내면서 지난 금요일에 &#39;중립&#39; 영역으로 이동했다.금요일(15일) 미국 증시는 다우존스 지수가 장중 300포인트 이상 하락하는 등 하락세로 마감했다. S&amp;P 500 지수는 주간 2.1%의 손실을 기록했고, 나스닥 종합 지수는 3.2% 정도 하락했다. 30개 종목으로 구성된 다우존스 지수는 한 주 동안 1.2% 하락했다.

美 경제지표 발표, 엔비디아와 MS 주가 하락 후 다우 지수 300p 이상 하락: 공포·탐욕 지수는 &#39;중립&#39;

Equities

암젠(NASDAQ:AMGN)의 주가는 실험적인 비만 약물인 마리타이드(MariTide)의 초기 시험에서 골밀도 손실이 밝혀진 후 화요일에 7% 이상 하락했으며, CNBC의 짐 크레이머는 이 소식이 경쟁사인 일라이 릴리(NYSE:LLY)에 이득이 될 수 있다고 언급했다.

암젠이 뼈 위험 데이터를 숨겼다면 일라이 릴리의 부진한 주가에 호재가 될지도: 짐 크레이머

Amgen Inc

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over <a href="https://www.benzinga.com/quote/LLY/news">the last month</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" alt="" class="wp-image-658564" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.
Could the selloff be an overreaction?
Read Also: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a>
<h2 class="wp-block-heading">Bearish Signals Galore For LLY Stock</h2>
Lilly stock is trading beneath its eight-, 20-, and 50-day exponential moving averages, firmly positioning it in a bearish trend. The Relative Strength Index (RSI) of 33.02 indicates the stock is teetering on oversold territory, while the MACD at negative 37.55 confirms strong downward momentum.
Even the 200-day simple moving average of $835.76 is now a distant memory, amplifying concerns.
<h2 class="wp-block-heading">Kennedy Sends Drugmakers Tumbling</h2>
The broader selloff in anti-obesity drugmakers like Eli Lilly, Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) has been linked to fears over the possible appointment by President-elect Donald Trump of Robert F. Kennedy Jr. as head of the Department of Health and Human Services.
Investors worry his critical stance on GLP-1 weight-loss treatments could lead to reduced insurance coverage or pricing pressures. While the agency has limited power to enact sweeping changes without Congress, the uncertainty has spooked the market.
<h2 class="wp-block-heading">Still Room To Run?</h2>
For contrarian investors, the fundamentals paint a different picture. Eli Lilly's Zepbound and Mounjaro sales are projected to hit $18 billion by 2026, doubling from 2024 estimates.
Total revenue is expected to climb to $69 billion by 2026, with earnings soaring to $30 per share — more than double the current $13.26.
And at 33.2 times forward earnings (per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), the stock's valuation looks far more attractive than its July peak of 57.2 times.
<h2 class="wp-block-heading">What's Next?</h2>
Jim Cramer's take sums up the contrarian sentiment: "This stock is as hated now as it was loved not that long ago. I think it's a buy&#8230; enough on the selling."
For long-term investors, Eli Lilly's dominance in the burgeoning obesity drug market remains a compelling growth story. 
Whether the selloff is a red flag or a golden opportunity may depend on how much faith investors have in the fundamentals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">Big Pharma&#8217;s Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a></li>
</ul>
Photo courtesy of Eli Lilly.

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

Financial giants have made a conspicuous bullish move on Amgen. Our analysis of options history for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $172,165, and 4 were calls, valued at $144,495.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $280.0 and $350.0 for Amgen, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Amgen stands at 1066.0, with a total volume reaching 267.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $280.0 to $350.0, throughout the last 30 days.
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732128618_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$22.0</td>
<td>$21.4</td>
<td>$21.55</td>
<td>$292.50</td>
<td>$60.3K</td>
<td>70</td>
<td align="right">51</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.8</td>
<td>$21.4</td>
<td>$21.5</td>
<td>$292.50</td>
<td>$45.1K</td>
<td>70</td>
<td align="right">51</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$17.44</td>
<td>$282.50</td>
<td>$43.7K</td>
<td>703</td>
<td align="right">113</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.5</td>
<td>$19.85</td>
<td>$20.5</td>
<td>$280.00</td>
<td>$40.9K</td>
<td>1.7K</td>
<td align="right">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$56.1</td>
<td>$53.95</td>
<td>$55.05</td>
<td>$335.00</td>
<td>$38.5K</td>
<td>310</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
<h3>Where Is Amgen Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,464,150, the price of AMGN is up by 1.67%, reaching $284.63.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Decoding Amgen's Options Activity: What's the Big Picture?

On Monday, Silence Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42046710/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-2024-american-heart-associa" rel="noreferrer noopener">levels (≥125 nmol/L)</a>.
These data were presented at the American Heart Association (AHA) Scientific Sessions.
Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks.
This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluate the effects of treatment over time, including intervals between doses.
Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted, and no safety concerns emerged with infrequent dosing.
William Blair notes that while Silence's data shows the drug effectively lowers Lp(a) levels, the Q24W dosing schedule may not be competitive. This is due to a decline in Lp(a) reduction between doses.
This dosing schedule could be an option for maintenance after stable Lp(a) reductions are reached. However, the analyst expects more frequent dosing, possibly every three months, to be needed. This may reduce zerlasiran's competitive edge compared to Amgen Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) olpasiran.
The analyst writes, "Silence continues to execute on both the zerlasiran and divesiran lead clinical programs. While data for zerlasiran presented at AHA show that zerlasiran is an efficacious Lp(a) lowering agent over 48 weeks with Q24W dosing, we are incrementally negative on zerlasiran's competitive profile given the waning of Lp(a) lowering between the infrequent doses, which has not been demonstrated with olpasiran at a once-quarterly dosing frequency."
Price Action: SLN stock is down 33.80% at $7.20 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Aclaris </a><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments</a></li>
</ul>

Analyst Color

Price Target

Analyst Ratings

Movers

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett <a href="https://www.benzinga.com/quote/NGNE">syndrome patient</a>.
Neurogene shares declined 37.7% to $21.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares tumbled 16.1% to $2.29 in pre-market trading after dipping over 20% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) tumbled 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares fell 7% to $6.28 in pre-market trading.</li>
<li>CompoSecure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) shares declined 5.9% to $13.00 in pre-market trading.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 5.4% to $266.21 in pre-market trading following a 4% decline on Friday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 5% to $11.80 in pre-market trading after jumping 21% on Friday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 4% to $3.67 in pre-market trading.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.4% to $138.51 in pre-market trading after declining more than 3% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

AMAT

CMPO

LAZR

LUNR

NGNE

OMER

PRQR

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index moving to the &#8220;Neutral&#8221; zone on Friday.
U.S. stocks settled lower on Friday, with the Dow Jones falling more than 300 points during the session. The S&amp;P 500 recorded a weekly loss of 2.1%, while the Nasdaq Composite fell around 3.2%. The 30-stock Dow lost 1.2% during the week.
Major tech stocks recorded losses, with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares falling over 3% on Friday, and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) stock losing around 2.8% during the session. However, shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained around 3% on Friday.
Shares of vaccine companies settled lower on Friday after President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dipped over 7%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares declined more than 4% during the session. The SPDR S&amp;P Biotech ETF dipped over 5%, recording its worst week since 2020.
On the economic data front, U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October. U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, topping market estimates of 0.3%
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, communication services, and healthcare stocks recording the biggest losses on Friday. However, utilities and financials stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 306 points to 43,444.99 on Friday. The S&amp;P 500 fell 1.32% to 5,870.62, while the Nasdaq Composite fell 2.24% at 18,680.12 during Friday's session.
Investors are awaiting earnings results from Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), and AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.9, the index moved to the &#8220;Neutral&#8221; zone on Friday, versus a prior reading of 58.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone

WIIM

GILD

IONS

VKTX

Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Events

Amgen To Present MITIGATE Phase 3 Study At ACR 2024 Nov. 14-19

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 4 are puts, totaling $137,540, and 4 are calls, amounting to $285,919.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $290.0 to $340.0 for Amgen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $290.0 to $340.0 in the last 30 days. 
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600944_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$43.6</td>
<td>$43.55</td>
<td>$43.6</td>
<td>$300.00</td>
<td>$196.2K</td>
<td>25</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$52.8</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$340.00</td>
<td>$51.5K</td>
<td>190</td>
<td align="right">19</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$9.2</td>
<td>$10.0</td>
<td>$310.00</td>
<td>$38.0K</td>
<td>1.8K</td>
<td align="right">62</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.65</td>
<td>$15.2</td>
<td>$15.45</td>
<td>$290.00</td>
<td>$33.9K</td>
<td>1.5K</td>
<td align="right">30</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.95</td>
<td>$2.08</td>
<td>$2.29</td>
<td>$340.00</td>
<td>$26.5K</td>
<td>112</td>
<td align="right">121</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 856,173, the AMGN's price is down by -2.03%, now at $295.33. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $360.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein downgraded its action to Outperform with a price target of $380. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Amgen, targeting a price of $380. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $335. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Amgen, maintaining a target price of $383. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $326. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Amgen's Options Frenzy: What You Need to Know

Analysts' ratings for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a low estimate of $215.00. Observing a 3.48% increase, the current average has risen from the previous average price target of $337.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1731592860_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$335.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Yaron Weber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$380.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$333.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$362.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amgen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amgen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amgen analyst ratings.</a>
<h2>Unveiling the Story Behind Amgen</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Amgen's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.18%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amgen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 42.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amgen's ROA stands out, surpassing industry averages. With an impressive ROA of 3.11%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Amgen's debt-to-equity ratio surpasses industry norms, standing at 8.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Amgen Stock

Citigroup analyst Geoff Meacham initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral rating and announces Price Target of $335.

Citigroup Initiates Coverage On Amgen with Neutral Rating, Announces Price Target of $335

On Tuesday, a Cantor analyst wrote that additional data from Amgen&#8217;s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
On Wednesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, &#8220;Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41932478/amgen-provides-statement-on-maritide-phase-1-data" rel="noreferrer noopener">later this year</a>.&#8221;
CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html" rel="noreferrer noopener">highlighted</a> that MariTide could be a strong new contender in the weight loss drug market. Unlike current weekly injections from Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), MariTide is taken once a month and works through a different mechanism.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41928127/jim-cramer-says-eli-lillys-pathetic-stock-performance-could-get-a-breather-if-amgen-has-hidden-bone-risk-data-after-7-stock-drop" rel="noreferrer noopener">Jim Cramer Says Eli Lilly&#8217;s &#8216;Pathetic&#8217; Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop</a>
Analysts referred to new public data from a phase one study, showing that the highest dose of MariTide (420 milligrams) was associated with around 4% decrease in bone mineral density over 12 weeks.
Goldman Sachs responded that after reviewing the data, they do not believe it shows any safety issues.
Goldman Sachs says BMD measurements from DEXA scans and believes concerns about the data are not justified as there is no significant difference between the treatment and placebo, nor any clear dose-dependent effect in the DEXA data.
The analyst also says a study by Amgen&#8217;s deCODE genetics, which included data from 1.2 million people, found no link between obesity-related variants in the GIPR gene and a higher risk of fractures or lower BMD. It&#8217;s already well-established that rapid weight loss is linked to BMD loss.
William Blair notes that at lower doses of AMG 133 (140 mg and 280 mg), the reduction in bone mineral density is minimal, around 2% at most, which might not differ significantly from the placebo due to limited data in smaller groups.
While the 4% reduction stands out compared to typical reductions of 2% to 2.5%, bariatric surgery has been known to reduce BMD by 3% to 5% after six months.
MariTide, which leads to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">more significant weight loss</a> over six months than semaglutide or liraglutide, may also result in greater BMD reductions due to this weight change.
Price Action: AMGN stock is up 1.39% at $302.98 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a></li>
</ul>

Large Cap

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

- UBS Healthcare Conference
<a href="https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html" title="https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html">https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html</a>

Amgen Executive Says Co Continues To Be "Laser Focused" On A Phase Three Development Program For Its Obesity Drug Maritide; Says Co Has Not Seen Any Association Between Administration Of Maritide And Bone Mineral Density Changes Or Safety Signals For Bone; Believe That A Research Note Had Suggested "An Inappropriate Inference" Of Maritide Data Given Its Limitations

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INCY

PTGX

10 Health Care Stocks With Whale Alerts In Today's Session

Live On CNBC, Joe Terranova Announces Sold Amgen

"The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year," Amgen said.

Amgen Issued The Statement On MariTide (Maridebart Cafraglutide, Formerly AMG 133) Phase 1 Data, Saying Amgen Does Not See An Association Between The Administration Of MariTide And Bone Mineral Density Changes

Amgen Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC&#8217;s Jim Cramer suggested the news could benefit rival Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
What Happened: Previously undisclosed data from MariTide&#8217;s Phase 1 trial showed a 4% decrease in bone mineral density among participants receiving a 420mg dose during the 12-week multiple ascending dose study. According to Olivia Brayer of Cantor Fitzgerald, the information emerged from hidden tabs in extended data files related to the trial.
MariTide, positioned as a monthly alternative to weekly injections offered by competitors Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly, operates through a different weight loss mechanism. The drug&#8217;s development has attracted significant attention due to its potential to disrupt the growing obesity treatment market.
&#8220;If Amgen has hidden bone risk data for its obesity drug, that&#8217;s huge news for Lilly which has become a pathetic stock of late,&#8221; Cramer wrote on X, formerly Twitter, announcing plans to discuss the implications at an upcoming meeting.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If Amgen has hidden bone risk data for its obesity drug , that&#39;s huge news for Lilly which has become a pathetic stock of late. Club name.. will talk about it at Thursday&#39;s meeting
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1856424358564245623?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/24/11/41927291/mara-holdings-soundhound-ai-spotify-rivian-tesla-why-these-5-stocks-are-on-investors-radars-today">MARA Holdings, SoundHound AI, Spotify, Rivian, Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Why It Matters: Despite concerns, Cantor Fitzgerald maintained its Overweight rating on Amgen with a $405 price target. The firm acknowledged that while some bone density loss is expected during weight loss treatments, particularly with a suboptimal diet, the dose-dependent increase in bone density loss could raise red flags.
The analysis also revealed data about AMG 598, a predecessor molecule that Amgen may have been investigating to challenge assumptions about GIPR antagonism&#8217;s role in bone density loss.
Price Action: Eli Lilly stock closed at $818.86 on Tuesday, down 1.63% for the day, with a slight drop of 0.10% in after-hours trading. Despite this, the stock has seen a strong 38.27% increase year-to-date. 
Meanwhile, Amgen ended the day at $298.84, down 7.14%. However, it saw a slight recovery after hours, rising 0.61%. Amgen's stock has gained 0.49% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41927913/amazon-confirms-vendor-data-breach-affecting-2-8m-employee-contacts-adds-to-growing-list-of-moveit-hack-victims">Amazon Confirms Vendor Data Breach Affecting 2.8M+ Employee Contacts, Adds To Growing List Of MOVEit Hack Victims</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop

Jefferies analyst Michael Yee maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Buy and maintains $380 price target.

Jefferies Maintains Buy on Amgen, Maintains $380 Price Target

Amgen shares are trading lower after Cantor Fitzgerald highlighted pipeline risks and a 4% BMD loss in its AMG-133 Phase 1 trial.

Guidance

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Eledon Pharmaceuticals (ELDN –...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN)

Geoff Meacham, an analyst from Citi, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target remains the same wit...

Cautious Hold Rating on Amgen's MariTide Amid Safety and Efficacy Concerns

XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)

Amgen (AMGN) announced that Howard Chang will join the company as Senior VP of Research, effective Dec. 16. Chang will also assume the title and re...

Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $380.00. T...

Jefferies Sticks to Their Buy Rating for Amgen (AMGN)

Optimism over global healthcare sector rises: Jefferies

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Evan Seigerman has given his B...

Evan Seigerman's Buy Rating on Amgen Driven by Positive MariTide Outlook and Undervaluation

Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735

AbbVie: Upgrading To 'Strong Buy' After Pullback

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

ABBV

ALHC

BIIB

CLOV

ELDN

ISRG

REGN

RHHBY

SNYNF

SPGI

TEVA

TEVJF

Press Releases

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS

Dividends

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND

Earnings

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

Legal

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Citigroup

Jefferies

Cantor Fitzgerald

TD Cowen

일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)의 최근 주가가 하락세를 보이고 있다. 지난해 주가가 26.04% 상승했지만 <a href="https://www.benzinga.com/quote/LLY/news" target="_blank" rel="noopener" data-google-interstitial="false">최근 한 달 동안</a>에는 17.24% 하락했다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-658564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" alt="" width="628" height="490" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">차트: Benzinga Pro</a>
현재 일라이 릴리의 주가는 여름 고점에서 크게 하락하여 746.94달러에 거래되고 있다. 한 때 인기가 높았던 이 비만 치료제 제조사는 현재 하락세의 기술적 신호와 정치적 불확실성의 영향을 받고 있다.
이번 매도세가 과도한 반응일까?
추가 읽기: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">일라이 릴리, 버지 지노믹스 ALS 약물 후보 개발 선택</a>
<h2 class="wp-block-heading">LLY 주식의 하락 신호</h2>
일라이 릴리의 주식은 8일, 20일  50일 지수 이동 평균선 이하로 거래되고 있어 확고한 하락세를 보이고 있다. 상대 강도 지수(RSI)는 33.02로 과매도 구역에 근접해 있으며, 이동평균 수렴발산(MACD)은 -37.55로 강한 하락 모멘텀을 확인해준다.
200일 단순 이동 평균인 835.76달러도 이제는 먼 기억이 되어 우려를 증폭시키고 있다.
<h2 class="wp-block-heading">케네디, 제약사 주가 하락의 원인</h2>
일라이 릴리와 함께 노보 노디스크 AS(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 및 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)과 같은 반비만 약물 제조사들의 주가 하락은 대통령 당선이 도널드 트럼프가 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 임명할 가능성에 대한 우려로 연결되었다.
투자자들은 케네디의 GLP-1 체중 감소 치료제에 대한 비판적인 입장이 보험 적용 축소나 가격 압박으로 이어질 수 있다고 우려하고 있다. 해당 기관이 의회 없이 광범위한 변화를 시행할 수 있는 권한은 제한적이지만, 불확실성은 시장을 위축시켰다.
<h2 class="wp-block-heading">상승 가능성은?</h2>
반대 투자자들에게는 근본적인 요소들이 다른 그림을 보여준다. 일라이 릴리의 젭바운드(Zepbound) 및 마운자로(Mounjaro) 매출은 2026년까지 180억 달러에 이를 것으로 예상되며, 이는 2024년 추정치의 두 배이다.
총 매출은 2026년까지 690억 달러로 증가할 것으로 예상되며, 주당 순이익은 현재의 13.26달러의 두 배 이상인 30달러로 급증할 것으로 보인다.
그리고 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> 데이터에 따르면, 선행 주가수익비율(PER)이 33.2배인 반면, 주식 가치는 7월의 57.2배 고점보다 훨씬 매력적으로 보인다.
<h2 class="wp-block-heading">향후 전망</h2>
짐 크레이머의 의견은 반대론자의 감정을 요약해준다: &#8220;이 주식은 얼마 전만 해도 사랑받던 주식만큼이나 지금은 미움을 받고 있다. 나는 이것이 매수할 만하다고 생각한다&#8230; 매도는 충분하다.&#8221;
장기 투자자들에게는 일라이 릴리의 비만 약물 시장에서의 지배력이 여전히 매력적인 성장 이야기로 남아 있다.
매도세가 경고 신호인지 아니면 좋은 기회인지는 투자자들이 기본 요소에 얼마나 신뢰를 두고 있는지에 따라 달라질 수 있다.
주가 움직임: 일라이 릴리의 주식은 목요일 0.46% 하락한 749.92달러에 마감되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">대제약사 약제비 관리자가 약제 리베이트 제도 개편에 대한 FTC의 과도한 개입을 비난</a></li>
</ul>
사진 출처: Eli Lilly.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 더 하락했음을 나타내면서 지난 금요일에 &#8216;중립&#8217; 영역으로 이동했다.
금요일(15일) 미국 증시는 다우존스 지수가 장중 300포인트 이상 하락하는 등 하락세로 마감했다. S&amp;P 500 지수는 주간 2.1%의 손실을 기록했고, 나스닥 종합 지수는 3.2% 정도 하락했다. 30개 종목으로 구성된 다우존스 지수는 한 주 동안 1.2% 하락했다.
주요 기술주들은 손실을 기록했으며, 특히 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 주가는 금요일에 3% 이상 하락했고, 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 주가는 세션 중 약 2.8% 하락했다. 그러나 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 금요일에 약 3% 상승했다.
제약주는 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 임명한 후 금요일 하락세로 마감했다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) 주가는 7% 이상 하락했고 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) 주가도 4% 이상 하락했다. SPDR S&amp;P 바이오테크 ETF는 5% 이상 하락하며 2020년 이후 최악의 한 주를 기록했다.
경제 데이터 측면에서 10월 미국 수출 가격은 전월 대비 0.8% 상승했고, 10월 수입 가격은 전월 대비 0.3% 상승했다. 10월 미국 소매판매는 전월 대비 0.4% 증가하여 9월 수정치 0.8%보다는 하락했고, 시장 예상치 0.3%는 상회했다.
정보 기술, 통신 서비스, 헬스케어 섹터가 금요일에 가장 큰 손실을 기록하면서 S&amp;P 500의 대부분의 업종이 마이너스로 마감했다. 그러나 유틸리티와 금융 섹터는 전체 시장 추세와 다르게 상승세로 마감했다.
금요일 다우존스 지수는 약 306포인트 하락한 43,444.99포인트로 마감했다. S&amp;P 500 지수는 1.32% 하락한 5,870.62포인트, 나스닥 종합지수는 2.24% 하락한 18,680.12포인트로 마감했다.
투자자들은 오늘 트립닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), 브래디 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), 에이컴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란? </h3>
CNN 공포·탐욕 지수는 현재 50.9를 기록하고 있다. 금요일에 &#8216;탐욕&#8217;에서 &#8216;중립&#8217; 영역으로 이동했으며, 이전 수치는 58.2였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%94%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%ED%95%B4%EC%95%BC-%ED%95%A0-%EC%A3%BC%EC%8B%9D-%EB%B8%8C%EB%9E%98%EB%94%94-%EC%97%90%EC%9D%B4%EC%BB%B4-it-%ED%85%8C%ED%81%AC-%ED%8C%A8%ED%82%A4/" target="_blank" rel="noopener">월요일 주목해야 할 주식: 브래디, 에이컴, IT 테크 패키징, 빗디어 및 트립닷컴</a>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

美 경제지표 발표, 엔비디아와 MS 주가 하락 후 다우 지수 300p 이상 하락: 공포·탐욕 지수는 '중립'

암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)의 주가는 실험적인 비만 약물인 마리타이드(MariTide)의 초기 시험에서 골밀도 손실이 밝혀진 후 화요일에 7% 이상 하락했으며, CNBC의 짐 크레이머는 이 소식이 경쟁사인 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)에 이득이 될 수 있다고 언급했다.
무슨 일이 (What Happened): 이전에 공개되지 않았던 마리타이드의 1상 시험 데이터에 따르면, 420mg 용량을 받은 참가자들에서 12주 간의 용량 증량 연구 동안 뼈 미네랄 밀도가 4% 감소했다고 한다. 캔터 피츠제럴드의 올리비아 브레이어(Olivia Brayer)에 따르면, 이 정보는 임상시험 관련 확장 데이터 파일의 숨겨진 탭에서 발견됐다.
마리타이드는 경쟁사인 노보노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 일라이 릴리가 제공하는 주간 주사제에 대한 월간 대체제로 포지셔닝되었으며, 체중 감소 메커니즘이 다르다. 이 약물의 개발은 성장하는 비만 치료 시장을 뒤흔들 가능성 때문에 큰 주목을 받고 있다.
&#8220;암젠이 자사의 비만 치료제에 대한 뼈 위험 데이터를 숨겼다면, 이는 최근 주가가 저조했던 릴리에게는 큰 뉴스이다&#8221;고 크레이머가 X(구 트위터)에  게시하며, 향후 회의에서 이 문제의 함의를 논의할 계획이라고 발표했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
If Amgen has hidden bone risk data for its obesity drug , that&#39;s huge news for Lilly which has become a pathetic stock of late. Club name.. will talk about it at Thursday&#39;s meeting
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1856424358564245623?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
참고: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%99%94%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%EB%B0%9B%EC%9D%80-%EC%A3%BC%EC%8B%9D-%EB%A7%88%EB%9D%BC-%ED%99%80%EB%94%A9%EC%8A%A4-%EC%82%AC%EC%9A%B4%EB%93%9C%ED%95%98%EC%9A%B4%EB%93%9C-ai/" target="_blank" rel="noopener">마라 홀딩스, 사운드하운드 AI, 스포티파이, 리비안, 테슬라: 왜 이 5개 주식이 오늘 투자자들의 레이더에 올랐는가</a>
왜 중요한가 (Why It Matters): 우려에도 불구하고 캔터 피츠제럴드는 암젠에 대해 비중확대 등급과 405달러의 목표 주가를 유지했다. 이 회사는 체중 감소 치료 중 뼈 밀도 감소가 일부 발생할 것으로 예상되지만, 특히 최적화되지 않은 식이요법으로 인해 용량 의존적인 뼈 밀도 감소가 발생할 수 있다는 점에서 경고 신호를 제기할 수 있다고 인정했다.
이 분석은 또한 암젠이 GIPR 길항제의 뼈 밀도 감소 역할에 대한 가정을 도전하기 위해 조사하고 있었던 선행 분자 AMG 598에 대한 데이터를 밝혀냈다.
가격 변동: 일라이 릴리의 주식은 화요일에 818.86달러로 마감되어 하루 동안 1.63% 하락했으며, 시간외 거래에서 0.10% 소폭 하락했다. 그럼에도 불구하고 주가는 올해 들어 38.27% 상승했다.
한편, 암젠은 이날 298.84달러로 마감되어 7.14% 하락했다. 그러나 시간외 거래에서 0.61% 소폭 상승했다. 암젠의 주가는 <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">벤징가 프로</a>의 데이터에 따르면 올해 들어 0.49% 상승했다.

다음 읽기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%84%EB%A7%88%EC%A1%B4-280%EB%A7%8C-%EB%AA%85-%EC%9D%B4%EC%83%81%EC%9D%98-%EC%A7%81%EC%9B%90-%EC%97%B0%EB%9D%BD%EC%B2%98%EC%97%90-%EC%98%81%ED%96%A5%EC%9D%84-%EB%AF%B8%EC%B9%98%EB%8A%94/" target="_blank" rel="noopener">아마존, 280만명 이상의 직원 연락처가 유출된 벤더 데이터 유출 확인, MOVEit 해킹 피해자 목록에 추가</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" target="_blank" rel="noopener" data-google-interstitial="false">재무 실적</a>을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다.
애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.
<h3 class="wp-block-heading">‘주식 선택자의 해&#8217;: S&amp;P 500에서 10% 상승</h3>
골드만삭스의 애널리스트들은 2024년을 &#8220;주식 선택자의 해&#8221;라고 부르며, 변동성이 큰 실적 환경에서 선택적 투자의 중요성을 강조했다.
이 투자은행의 최신 전망에 따르면, 평균 S&amp;P 500 주식은 향후 12개월 동안 10%의 상승 잠재력을 가질 수 있다.
&#8220;우리는 반등 가능성을 보고 있다&#8221;고 마샬이 그의 노트에서 언급했다. &#8220;옵션 시장의 방향성 포지셔닝이 균형을 이루고 있어, 지난 분기 이맘때보다 훨씬 나은 설정이다.&#8221;
또한 이 애널리스트들은 최근 헤지 펀드와 소매 트레이더들 모두의 옵션 시장 활동이 감소하여, 투자자들이 3분기 실적 보고서와 다가오는 미국 선거를 준비하면서 &#8220;관망하는(wait-and-see)&#8221; 태도를 취하고 있음을 나타냈다.
<h3 class="wp-block-heading">실적 시즌의 변동성은 여전히 높다</h3>
골드만삭스는 실적 이벤트를 둘러싼 개별 주식의 변동성이 14년 만에 최고 수준에 있다고 강조했다.
인공지능(AI), 금리 그리고 다가오는 선거와 같은 주요 시장 논쟁이 이 추세를 주도하고 있으며, 이는 연말까지 계속될 것으로 예상된다.
&#8220;우리는 실적 발표일의 주가 변동이 여전히 높을 것으로 예상하며, 이는 시장의 주요 논쟁들이 주식 공간에서 승자와 패자를 만들어내기 때문이다,&#8221;라고 이 노트에 추가했다.
이러한 높은 변동성 속에서, 이 회사는 옵션 기반 전략을 계속 추천하며, 투자자들에게 실적 이벤트 전 옵션을 매수하고 실적 기간 사이에 옵션을 매도하여 가격 변동을 활용할 것을 권장했다.
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 긍정적으로 평가한 18개 주식</h3>
골드만삭스의 애널리스트들은 실적 조정이 긍정적으로 작용할 수 있다고 믿는 18개의 주식을 선정했다. 이 주식들은 에너지, 금융, 헬스케어, 기술 등 다양한 부문에 걸쳐 있다.
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>갭 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>소비재</td>
<td>11월 15일</td>
</tr>
<tr>
<td>퍼미안 리소스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>에너지</td>
<td>11월 7일</td>
</tr>
<tr>
<td>씨티그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>금융</td>
<td>10월 15일</td>
</tr>
<tr>
<td>싱크로니 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>금융</td>
<td>10월 16일</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>헬스케어</td>
<td>10월 23일</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>헬스케어</td>
<td>10월 31일</td>
</tr>
<tr>
<td>퀴아젠 NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>AZEK 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>산업재</td>
<td>11월 29일</td>
</tr>
<tr>
<td>ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>11월 1일</td>
</tr>
<tr>
<td>브로드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>12월 6일</td>
</tr>
<tr>
<td>델 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>11월 25일</td>
</tr>
<tr>
<td>클라비요 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>먼데이닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>11월 13일</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>11월 21일</td>
</tr>
<tr>
<td>스노우플레이크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>11월 29일</td>
</tr>
<tr>
<td>토스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셈프라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>유틸리티</td>
<td>11월 4일</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 비관적으로 평가한 7개 주식</h3>
반대로, 이 투자은행은 3분기 실적에서 하향 조정의 영향을 받을 것으로 예상되는 7개 주식을 선정하여 투자자들에게 주의할 것을 권고했다.
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>초이스호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>소비재</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셰니에르 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>에너지</td>
<td>11월 1일</td>
</tr>
<tr>
<td>야누스 헨더슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>금융</td>
<td>10월 31일</td>
</tr>
<tr>
<td>라이온델바젤 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>소재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크로락스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>소비재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크래프트 하인즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>소비재</td>
<td>10월 30일</td>
</tr>
<tr>
<td>업스타트 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
</tbody>
</table>
</figure>
다음 글 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">연준의 굴스비가 인플레이션 상승을 경시하며, 경제학자들은 11월 금리 인하 발표에 대한 입장을 고수합니다.</a></li>
</ul>
이미지는 Midjourney를 통해 인공지능으로 생성되었습니다.

Mid Cap

Tech

ETFs

AVGO

AZEK

DELL

KVYO

MNDY

QGEN

SNOW

TOST

UPST

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 '주식 선택자의 해'

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 <a href="https://www.benzinga.com/exclusives">벤징가(Benzinga)와의 독점 인터뷰</a>에서 그의 낙관적인 예측을 공유했다. 
마우리츠는 &#8220;장기적으로 이것은 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 사이의 양대 경쟁이 아니라고 생각한다&#8221;고 말하며, 체중 감량 시장에서 널리 퍼져 있는 두개의 기업이 전체 시장을 과점(duopoly)하는 개념에 도전했다.
Pot은 체중 감량 치료제에 대한 수요 증가와 GLP-1 약물의 적용 확대가 이 1조 달러 규모의 시장 기회를 주도할 것이라고 예측한다.
2023년 11월, 테마 ETFs는 체중 감량에 초점을 맞춘 최초의 ETF인 Tema GLP-1, Obesity and Cardiometabolic ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>)를 출시했다. SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)에서 추적한 바와 같이, 이 펀드는 개시 이후 25% 상승하여 S&amp;P 500의 성과를 약간 앞섰다.
이 ETF의 주요 보유 종목으로는 일라이 릴리, 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), 노보 노디스크, 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 있으며 각각 약 5~6%의 비중을 갖고 있다. 이 HRTS 포트폴리오는 또한 40개 이상의 기타 체중 감량 관련 회사들로 구성되어 있다.
차트: Tema GLP-1, Obesity and Cardiometabolic ETF는 설정 이후 S&amp;P 500을 능가
<figure class="wp-block-image size-large"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-422177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-300x191.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-768x489.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1536x978.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10.png 1662w" alt="" width="1024" height="652" /></a></figure>
차트: <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1">벤징가 프로</a> 
<h3 class="wp-block-heading">체중 감량 치료: 응용 분야 및 혁신 확대</h3>
팟(Pot)에 따르면, GLP-1 약물은 곧 체중 감량을 넘어 당뇨병, 심장, 간 및 신장 질환에 적용되고 암, 알츠하이머병, 파킨슨병 및 기타 신경성 질환과 같은 질환을 치료할 수 있는 가능성이 있다고 한다.
기존 주사 방법은 경구 투여 또는 투여 빈도 감소에 초점을 맞춘 새로운 접근법으로 인해 어려움을 겪고 있다. 혁신의 목표는 주 1회 주사에서 잠재적으로 2개월에 한 번으로 전환하는 등 치료법을 덜 침습적으로 만들거나 경구 정제 생산과 같이 제조하기를 훨씬 쉽게 만드는 것이다.
비만은 당뇨병, 심장병, 암 등 다양한 질병을 유발한다. 따라서 비만을 해결하면 여러 가지 건강 문제를 완화하고 GLP-1 약물의 시장 잠재력을 증폭시킬 수 있다.
이 시장은 일라이 릴리 및 노보 노디스크를 넘어 다양한 질병 영역을 다루게 될 것으로 예상된다.
팟은 비만, 당뇨병, 잠재적으로 알츠하이머병이나 암에 대한 용도를 언급하면서 &#8220;세계 인구의 절반이 GLP-1이나 다른 체중 감량 약물을 1차 예방 등의 다른 이유로 복용하는 세상을 볼 수 있다&#8221;라고 말했다.
<h3 class="wp-block-heading">1조 달러 예상의 배경</h3>
전 세계 비만 인구는 2035년까지 10억 명에서 20억 명으로 두 배로 늘어날 것으로 예상된다. 이러한 성장이 없더라도 기존 10억 명의 비만 인구는 상당한 시장을 대표한다.
장기 치료가 현재 비만 인구의 20%에게만 도달한다면, 이는 현재 당뇨병 약물의 보급률과 유사하게 2억 명에 해당한다. 연간 1인당 약가가 12,000달러에서 6,000달러로 인하된다고 가정하면 GLP-1 의약품 시장은 1조 달러를 넘어설 수 있다고 팟이 설명했다.
골드만삭스는 시장 규모를 1,000억~1,300억 달러로 추정하지만 팟은 암, 알츠하이머병, 파킨슨병에 대한 투기적 적용을 고려하기 전에도 시장이 1조 달러에 도달할 수 있다고 믿고 있다. 시장 규모는 지속적으로 과소평가되어 왔으며 추정치는 몇 달마다 증가하고 있다.
특허 만료는 또한 시장을 형성할 것이다. 미국에서는 오젬픽(Ozempic)/위고비(Wegovy)의 특허가 2032년에 만료되고, 유럽에서는 2031년, 중국에서는 2026년에 만료된다.
"특허가 만료되기 전에는 1조 달러 규모의 시장이 될 것이라고 생각한다"라고 팟은 말했다.
<h3 class="wp-block-heading">중소형주에 초점 맞추기</h3>
왜 투자자들이 소수의 대형주 대신 다양한 체중 감량 관련 주식에 집중해야 하는지 묻는 질문에 팟은 일라이 릴리와 같은 대기업들과 달리 &#8220;이 거대한 중소형 생명공학 시장에서 긍정적인 임상 결과의 영향이 훨씬 더 높다&#8221;고 설명했다. 
그는 포트폴리오 균형으로 대형주를 보유하는 것의 중요성을 강조했지만 소규모 회사들이 장기적으로 더 높은 수익을 제공할 수 있다고 지적했다.
팟은 생명공학 부문이 인수합병으로 성숙해 있음을 강조했다. 지난해에만 가치가 10억 달러를 초과하는 생명공학 M&amp;A 거래가 22건 있었다.
머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), 또는 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 같이 비만 사업이 없는 주요 헬스케어 회사들이 인수를 모색할 가능성이 높다.
지금 읽기
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/06/39143220/exclusive-tema-american-reshoring-etf-outshines-s-p-500-without-owning-magnificent-7-stocks-they-can">단독: Tema American Reshoring ETF는 7개 주식을 보유하지 않고도 S&amp;P 500을 능가</a></li>
</ul>
사진: 셔터스톡


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Sector ETFs

Small Cap

Global

Exclusives

ALNY

HRTS

단독: GLP-1 체중 감량 약물은 수조 달러 규모의 시장 가능성, 테마 ETFs CEO의 전망

S&amp;P 500과 나스닥 100 지수는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39618958/us-services-sector-activity-experiences-largest-contraction-in-over-4-years-gold-ra" target="_blank" rel="noopener" data-google-interstitial="false">2020년 5월 이후 최악의 위축</a>을 겪은 6월 서비스 부문 활동이 예상보다 크게 낮아지자 투자자들이 금리 인하에 대한 기대를 높이면서 목요일 사상 최고치를 경신했다.
CME 그룹의 페드워치(FedWatch) 도구에 따르면 9월 연방준비제도(연준)의 금리 인하 가능성은 65%에서 72%로 증가했다. 트레이더들은 연말까지 50bp(베이시스 포인트) 이상의 금리 인하 가격을 책정했다. 이는 연준이 두 번의 금리 인하를 시사한다.
특히 미국 동부 시간 오후 2시에 발표될 연방공개시장위원회(FOMC) 의사록을 앞두고 위험 심리가 강했다.
iShares Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>)가 추적하는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 칩 제조 산업은 각각 3.7%와 1.9% 상승했다.
VanEck Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)가 4.2% 상승하는 등 금 광산주 부문에서도 강한 상승세를 보였다. 이는 금속 가격 상승에 힘입어 올해 현재까지 가장 성과가 좋은 세션 중 하나를 기록했다.
금리 하락에 대한 기대감으로 금 가격은 1.4%, 은은 3.5%, 구리는 2.6% 상승했다.
국채 수익률은 10년물과 30년물 수익률이 모두 7bp 하락하는 등 급격하게 약세를 보였다. iShares 20+ Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 1.1% 상승해 6월 13일 이후 가장 높은 상승률을 기록했다.
그러나 크립토 시장은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)이 60,450달러로 2.7% 하락했다.
<h3 class="wp-block-heading">주요 미국 지수와 ETF의 수요일 성과</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>1일 변동률</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>20,168.73</td>
<td>0.8%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,531.06</td>
<td>0.4%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>202.16</td>
<td>0.1 %</td>
</tr>
<tr>
<td>다우 존스</td>
<td>39,273.72</td>
<td>-0.1%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">동부시간 12:28 p.m. 기준</figcaption></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070324&amp;t=be2bearmibe3na1">Benzinga Pro</a>의 데이터에 따르면:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 0.3% 상승한 550.85달러로 마감했다.</li>
<li>SPDR 다우존스 산업평균 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)가 0.2% 하락한 392.45달러로 마감했다.</li>
<li>기술주 중심의 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.8% 상승한 490.70달러를 기록했다.</li>
<li>Technology Discretionary Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 1.3% 상승했으며, 이에 비해 Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)는 1% 하락했다.</li>
</ul>
<h3 class="wp-block-heading">수요일 주식 변동:</h3>
<ul>
<li>체중 감량 약물 대기업인 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 매사추세츠 아이 앤드 이어(Massachusetts Eye and Ear)에서 실시한 연구에서 오젬픽(Ozempic)과 위고비(Wegovy)가 실명의 눈 질환 위험이 더 높은 것으로 나타난 후 각각 1.9%와 4% 하락했다. 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)과 바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)도 각각 1.9%, 2.2% 하락했다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주가는 화요일부터 전기 자동차 제조업체의 분기별 납품 실적이 예상보다 좋은 이후 5.5% 상승하는 등 상승 모멘텀을 이어갔다.</li>
<li>기타 전기차 관련 주식도 상승세를 보였는데, 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)가 8%, 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)가 15% 상승했다.</li>
<li>파라마운트 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)은 스카이댄스(Skydance)가 파라마운트의 지배 회사인 내셔널 어뮤즈먼트(National Amusements) 인수 거래에 다시 관심을 갖고 있다는 월스트리트 저널의 소문에 따라 7% 이상 급등했다.</li>
<li>콘스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)는 지난 분기 매출이 예상보다 낮은 가운데, 4.4% 하락해 2023년 10월 이후 최악의 세션을 기록했다.</li>
</ul>

Comments

Amgen

뉴스

에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

금요일, 11월 22, 2024

월요일, 11월 18, 2024

수요일, 11월 13, 2024

금요일, 10월 11, 2024

일요일, 7월 07, 2024

목요일, 7월 04, 2024

월요일, 5월 06, 2024

금요일, 5월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌